Clinical trials of low-dose IL-2 in patients have had selective effects on T regs in healthy individuals, patients with hepatitis C virus-induced vasculitis, type 1 diabetes, and systemic lupus erythematosus [39,40,41,42]. Here, IL2 is linked to type 1 diabetes mellitus.